Display options
Cite
Freeman B, Lester S, Mills L, et al. Validation of a SARS-CoV-2 spike protein ELISA for use in contact investigations and serosurveillance. bioRxiv. 2020;doi: 10.1101/2020.04.24.057323.
Freeman, B., Lester, S., Mills, L., Rasheed, M. A. U., Moye, S., Abiona, O., Hutchinson, G. B., Morales-Betoulle, M., Krapinunaya, I., Gibbons, A., Chiang, C. F., Cannon, D., Klena, J., Johnson, J. A., Owen, S. M., Graham, B. S., Corbett, K. S., & Thornburg, N. J. (2020). Validation of a SARS-CoV-2 spike protein ELISA for use in contact investigations and serosurveillance. bioRxiv : the preprint server for biology, . https://doi.org/10.1101/2020.04.24.057323
Freeman, Brandi, et al. "Validation of a SARS-CoV-2 spike protein ELISA for use in contact investigations and serosurveillance." bioRxiv : the preprint server for biology vol. (2020). doi: https://doi.org/10.1101/2020.04.24.057323
Freeman B, Lester S, Mills L, Rasheed MAU, Moye S, Abiona O, Hutchinson GB, Morales-Betoulle M, Krapinunaya I, Gibbons A, Chiang CF, Cannon D, Klena J, Johnson JA, Owen SM, Graham BS, Corbett KS, Thornburg NJ. Validation of a SARS-CoV-2 spike protein ELISA for use in contact investigations and serosurveillance. bioRxiv. 2020 Apr 25; doi: 10.1101/2020.04.24.057323. PMID: 32511332; PMCID: PMC7239067.
Copy Download .nbib Format: NLM
Share it on

bioRxiv. 2020 Apr 25; doi: 10.1101/2020.04.24.057323.

Validation of a SARS-CoV-2 spike protein ELISA for use in contact investigations and serosurveillance.

bioRxiv : the preprint server for biology

Brandi Freeman, Sandra Lester, Lisa Mills, Mohammad Ata Ur Rasheed, Stefany Moye, Olubukola Abiona, Geoffrey B Hutchinson, Maria Morales-Betoulle, Inna Krapinunaya, Ardith Gibbons, Cheng-Feng Chiang, Deborah Cannon, John Klena, Jeffrey A Johnson, Sherry Michele Owen, Barney S Graham, Kizzmekia S Corbett, Natalie J Thornburg

Affiliations

  1. Centers for Disease Control and Prevention, Atlanta GA.
  2. Synergy America, Inc, Duluth GA.
  3. Eagle global Scientific, LLC, Atlanta, GA.
  4. Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda MD.

PMID: 32511332 PMCID: PMC7239067 DOI: 10.1101/2020.04.24.057323

Abstract

Since emergence of SARS-CoV-2 in late 2019, there has been a critical need to understand prevalence, transmission patterns, to calculate the burden of disease and case fatality rates. Molecular diagnostics, the gold standard for identifying viremic cases, are not ideal for determining true case counts and rates of asymptomatic infection. Serological detection of SARS-CoV-2 specific antibodies can contribute to filling these knowledge gaps. In this study, we describe optimization and validation of a SARS-CoV-2-specific-enzyme linked immunosorbent assay (ELISA) using the prefusion-stabilized form of the spike protein [1]. We performed receiver operator characteristic (ROC) analyses to define the specificities and sensitivities of the optimized assay and examined cross reactivity with immune sera from persons confirmed tohave had infections with other coronaviruses. These assays will be used to perform contact investigations and to conduct large-scale, cross sectional surveillance to define disease burden in the population.

References

  1. Science. 2020 Mar 13;367(6483):1260-1263 - PubMed
  2. JAMA. 2020 Mar 23;: - PubMed
  3. Emerg Infect Dis. 2020 Mar 31;26(7): - PubMed
  4. Clin Infect Dis. 2020 Mar 28;: - PubMed
  5. MMWR Morb Mortal Wkly Rep. 2020 Apr 03;69(13):377-381 - PubMed
  6. Sci Rep. 2019 Feb 4;9(1):1390 - PubMed
  7. Lancet. 2020 Feb 15;395(10223):497-506 - PubMed
  8. Emerg Infect Dis. 2020 Apr 08;26(7): - PubMed
  9. Lancet Infect Dis. 2020 May;20(5):565-574 - PubMed
  10. Lancet Infect Dis. 2020 Apr;20(4):410-411 - PubMed
  11. BMJ. 2020 Apr 7;369:m1395 - PubMed

Publication Types